Fludeoxyglucose F 18

Fludeoxyglucose F 18

Fludeoxyglucose F 18 Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.


Fludeoxyglucose F18 Injection is indicated for positron emission tomography (PET) imaging in the following settings:
1.1 Oncology
For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer.
1.2 Cardiology
For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging.
1.3 Neurology
For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures.


There is currently no drug history available for this drug.

Other Information

11.1 Chemical Characteristics
Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging. The active ingredient 2-deoxy-2-[18F]fluoro-D-glucose has the molecular formula of C6H1118FO5 with a molecular weight of 181.26, and has the following chemical structure:

Chemical Characteristics

Fludeoxyglucose F 18 Injection is provided as a ready to use sterile, pyrogen free, clear, colorless citrate buffered solution. Each mL contains between 0.15 to 18.5 GBq (4.0 - 500 mCi) of 2-deoxy-2-[18F]fluoro-D-glucose at the EOS, 9.0 mg of sodium chloride in citrate buffer. The pH of the solution is between 5.5 and 7.5. The solution is packaged in a multiple-dose glass vial and does not contain any preservative.
11.2 Physical Characteristics
Fluorine F 18 decays by emitting positron to Oxygen O 18 (stable) and has a physical half-life of 109.7 minutes. The principal photons useful for imaging are the dual 511 keV gamma photons, that are produced and emitted simultaneously in opposite direction when the positron interacts with an electron (Table 2).
Table 2. Principal Radiation Emission Data for Fluorine F 18
Radiation/Emission % Per Disintegration Mean Energy

Positron(β+) 96.73 249.8 keV
Gamma(±) 193.46 511.0 keV

The specific gamma ray constant (point source air kerma coefficient) for fluorine F 18 is 5.7 R/hr/mCi (1.35 x 10 -6 Gy/hr/kBq) at 1 cm. The half-value layer (HVL) for the 511 keV photons is 4 mm lead (Pb). The range of attenuation coefficients for this radionuclide as a function of lead shield thickness is shown in Table 3. For example, the interposition of an 8 mm thickness of Pb, with a coefficient of attenuation of 0.25, will decrease the external radiation by 75%.

Table 3. Radiation Attenuation of 511 keV Photons by lead (Pb) shielding
Shield thickness
(Pb) mm Coefficient of
0 0.00
4 0.50
8 0.25
13 0.10
26 0.01
39 0.001
52 0.0001
For use in correcting for physical decay of this radionuclide, the fractions remaining at selected intervals after calibration are shown in Table 4.

Table 4. Physical Decay Chart for Fluorine F 18
Minutes Fraction Remaining

0 1.000
15 0.909
30 0.826
60 0.683
110 0.500
220 0.250

Fludeoxyglucose F 18 Manufacturers

  • Spectron Mrc, Llc
    Fludeoxyglucose F 18 Injection [Spectron Mrc, Llc]
  • Global Isotopes, Llc D/b/a Zevacor Molecular
    Fludeoxyglucose F 18 Injection [Global Isotopes, Llc D/b/a Zevacor Molecular]
  • Centre For Probe Development And Commercialization
    Fludeoxyglucose F 18 Injection [Centre For Probe Development And Commercialization]
  • Triad Isotopes, Inc.
    Fludeoxyglucose F 18 (Fludeoxyglucose F-18) Injection, Solution [Triad Isotopes, Inc.]
  • Iba Molecular North America, Inc.
    Fludeoxyglucose F 18 (Fludeoxyglucose F-18) Injection [Iba Molecular North America, Inc.]
  • Petnet Solutions, Inc.
    Fludeoxyglucose F 18 Injection, Solution [Petnet Solutions, Inc.]
  • Washington University School Of Medicine
    Fludeoxyglucose F 18 Injection [Washington University School Of Medicine]
  • University Of California, Los Angeles
    Fludeoxyglucose F 18 Injection [University Of California, Los Angeles]
  • Uihc-p E T Imaging Center
    Fludeoxyglucose F 18 (Fludeoxyglucose F-18) Injection [Uihc-p E T Imaging Center]
  • The General Hospital Corporation
    Fludeoxyglucose F 18 (Fludeoxyglucose F-18) Injection, Solution [The General Hospital Corporation ]

Login To Your Free Account